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Severe metabolic acidosis is common among critically ill patients, and topiramate is a rare cause 
that may fail recognition. We report a lady with acute encephalopathy who had severe non-anion 
gap metabolic acidosis that served as the clue leading to suspicion and diagnosis of topiramate 
toxicity and was confirmed by elevated blood topiramate levels. Additionally, we provide a 
review of literature on all reported cases of topiramate toxicity.  
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BACKGROUND: 
 
Topiramate, used for epilepsy and migraine 
prophylaxis, acts by blocking neuronal 
voltage-dependent sodium channels, 
enhancing gamma-aminobutyric acid 
(GABA) A activity and antagonizing alpha-
amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA)/kainite 
glutamate receptors [1]. It also inhibits 
carbonic anhydrase (CA) causing a non-
anion gap metabolic acidosis (NAGMA). In 
clinical studies, 32% of patients consuming 
topiramate 400 mg had a serum bicarbonate 
decline to <20 mEq/L with a mean decline ~ 
5.1 mEq/L [2]. Dose reduction or 
discontinuation may be required for 
persistent, symptomatic or severe acidosis. 
We discuss a young lady with topiramate 
toxicity where a severe NAGMA was the 
key finding leading to the diagnosis. We 
also provide a brief review of literature 
pertaining to metabolic acidosis from 
topiramate toxicity. 
 
CASE: 
 
A 29-year-old Caucasian female presented 
to a referring facility with altered mental 
status. Her symptoms began the previous 
night with migraines for which she took her 
usual pills. Her home medications included 
sumatriptan, bupropion, topiramate and 
clonazepam. At 11:30 PM, while walking 
downstairs, she sustained a fall without loss 
of consciousness or injuries. By 5:30 AM 
the next day, her husband noticed abnormal 
twitching movements of her upper and lower 
extremities. Since he believed it to be a 
symptom of restless leg syndrome, he did 
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not wake her up. An hour later, she was 
found to be unresponsive to verbal or 
physical stimuli, her eyes were rolled up and 
a she had a rapid pulse. The husband called 
emergency services and she was transported 
to the referring facility. Per husband, she 
was more depressed over the previous 3 
days, and recently her physician increased 
her dose of clonazepam. At the referring 
facility, the patient was intubated using 
paralytics due to shallow breathing and for 
airway protection. She received two liters of 
0.9% saline to resolve hypotension. Labs 
were significant for a white blood cell 
counts (WBC) of 14.7 x 10-3/µL, sodium of 
140 mEq/L, potassium of 3.2 mEq/L, 
chloride of 103 mEq/L, and a bicarbonate of 
19.7 mEq/L. Serum total protein was 7.5 
g/dL, albumin was 3.6 g/dL, glucose was 
114 mg/dL, blood urea nitrogen was 17 
mg/dL, serum creatinine was 1.0 mg/dL, and 
osmolality was 282 mosm/L.  Urinalysis 
was normal, urine drug screen and 
pregnancy test were negative, and chest x-
ray had no abnormalities. The 
echocardiogram showed a hyperdynamic left 
ventricle, but was otherwise unremarkable. 
The patient was air lifted to our university 
hospital for further evaluation, with a 
concern for anoxic brain injury.  
 At arrival to our medical intensive 
care unit (MICU), vitals were normal, she 
was unresponsive with periodic spontaneous 
eye opening and non-purposeful movements 
in all extremities.  Bilateral pupils were 
dilated and reacted minimally to light. Deep 
tendon reflexes were normal. Rest of the 
exam was unremarkable. Blood tests results 
were as follows: WBC of 13.27 x 10-3/µL, 
serum sodium of 140 mmol/L, potassium of 
3.8 mmol/L, chloride of 111 mmol/L, 
bicarbonate of 16 mmol/L, lactic acid of 2.8 
mmol/L, creatinine of 0.76 mg/dL, and 
blood urea nitrogen of 15 mg/dL. Liver 
functions tests were also normal. Arterial 
blood gas revealed a pH of 7.166, pCO2 of 
40.0 mmHg, pO2 of 316 mmHg, HCO3 of 
13.9 mmol/L, and serum osmolality of 292 
mOsm/kg (Osmolar gap 3 mOsm/kg). Urine 
pH was 5 and urine electrolytes showed: 
sodium of 82 mmol/L, potassium of 26.7 
mmol/L, chloride of 96 mmol/L (urine anion 
gap 12.7 mmol/L) and creatinine of 59 
mg/dL. She was empirically started on 
vancomycin, ceftriaxone and acyclovir. 
Lumbar puncture was done and 
cerebrospinal fluid (CSF) results were 
normal (colorless, protein of 43 mg/dL, 
glucose of 60 mg/dL, no white or red blood 
cells). Subsequently, the antibiotics were 
stopped. Computerized tomography (CT) 
scan of the head and neck was also normal. 
Electroencephalography was reported to be 
consistent with moderate to severe 
encephalopathy of no specific etiology. 
Comprehensive drug screen was positive for 
naproxen and bupropion.   
 Given severe NAGMA and no other 
abnormalities in lab and imaging studies, we 
explored different causes of NAGMA and 
they were non-revealing. Past medical 
history was negative for diarrhea, previous 
abdominal processes, hyper-alimentation, 
chronic kidney disease or clues to inherited 
disorders, such as hearing loss, osteopetrosis 
or mental retardation (Table 1) [3]. We 
suspected topiramate toxicity based on its 
inhibition of CA. At approximately 12:30 
PM (~13 hours after the suspected ingestion) 
a topiramate level was drawn and sent to our 
reference laboratory (Mayo Medical 
Laboratories, Rochester, MN). She was 
given 0.45% normal saline with 75 mEq of 
sodium bicarbonate at 75 ml/hr based on 
evidence from our literature search on 
topiramate toxicity (see below in 
discussion).  Repeat blood gas later showed 
a pH of 7.345. On day 2, she spontaneously 
opened her eyes and followed commands. 
She was successfully extubated on day 3. 
Comprehensive drug screen returned with 
naproxen and bupropion being positive and 
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Table 1. Common Causes of Non-Anion Gap Metabolic Acidosis 
Low/Low-Normal Serum Potassium 
• Diarrhea 
• Uretero-enteric fistulas 
• Pancreatic/biliary drainage 
• Urinary intestinal diversion 
• Proximal RTA (type 2) 
• Distal RTA (type 1) 
• Carbonic anhydrase inhibitor 
• Toluene intoxication, D-lactic acidosis 
High/High-Normal Serum Potassium 
• Hyperkalemic distal RTA 
• Chronic kidney disease 
• Hyporeninemic hypoaldosteronism 
• Gordon syndrome 
• High ileostomy output 
• Decreased distal sodium delivery 
• Hydrochloric acid administration 
• Drug related (ie, NSAIDs, triamterene, trimethoprim, amiloride, heparin, pentamidine, spironolactone, 
ARB, ACEi) 
 
[ Reprinted from American Journal of Kidney Diseases, Vol 69(2), Mandena Rastegar and Glenn T Nagami, Non-
Anion Gap Metabolic Acidosis: A Clinical Approach to Evaluation, 296-301., 2016, with permission from Elsevier] 
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID, 
nonsteroidal antiinflammatory drug; RTA, renal tubular acidosis. 
 
topiramate level was reported as 20.5 
µg/mL. By day 4, her mental status was 
normal and she recalled taking additional 
doses of a migraine medication, but she was 
unsure if it was topiramate. She was 
discharged home the same day with a plan 
for an outpatient follow up with her 
preferred neurologist to consider alternatives 
for migraine prophylaxis other than 
topiramate. After a few months, per phone 
conversation with husband, the patient was 
reported to be asymptomatic and remained 
off topiramate since discharge.  
 
DISCUSSION: 
 
Common adverse effects from topiramate 
are neurological, including paresthesia, 
somnolence, fatigue, dizziness, mood and 
memory impairment, lack of concentration, 
confusion, headache, psychomotor 
retardation, agitation, cognitive dysfunction, 
ataxia, pain, as well as sensory and speech 
disturbances [2, 4-6]. Less commonly a 
variety of gastrointestinal symptoms have 
also been described [6]. Several reports 
describe toxicity at varying doses of 
ingestion when used for migraine and 
epilepsy (Table 2) [4, 5, 7-20]. Based on a 
retrospective review of 567 cases of 
topiramate toxicity (during 2000-2001), the 
American Association of Poison Control 
revealed that: 39% were adults, mild mental 
status changes were common, and severe 
respiratory depression or persistent 
NAGMA were infrequent yet other reports 
confirm their occurrence [5, 10-12]. 
NAGMA was of high diagnostic value in 
our patient’s case as history was negative for 
any other causes of NAGMA enumerated in 
Table 1 [3]. Type 1 or distal renal tubular 
acidosis (RTA) is characterized by an  
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Table 2. List of reported cases with topiramate toxicity. Literature review included only those reported in English 
language. Search terms in PUBMED and Google Scholar included “topiramate” and one or more of “toxicity”, 
“metabolic acidosis” and “overdose”.  
First 
Author 
(Ref no) 
Year No: 
of 
cases 
Dose Clinical 
Features 
Biochemical 
abnormalities at 
admission 
Treatment Outcomes 
Chun-
hung (12)  
2001 2 300 mg/day 
for 1 
weeks; 
unknown 
for second 
patient 
Hyperventilati
on; Increased 
irritability 
Case 1: pH 7.36, 
HCO3 14.9 
mEq/L;  
Case 2: pH 7.34, 
HCO3 20.4 
mEq/L 
Sodium 
bicarbonate; 
discontinued 
topiramate 
Full recovery 
Fakhoury 
(5) 
2002 2 Case 1: 
20,000 mg 
Case 2: 
40,000 mg 
Obtundation, 
Seizures, 
myoclonic 
jerks 
Case1: pH 7.22, 
HCO3 12 mEq/L. 
Case 2: pH 7.41, 
HCO3 12 mEq/L 
Both needed 
intubation for 
airway 
protection, 
intravenous 
fluids, 
antiepileptics 
Both had full 
recovery. 
Case 1: mental 
status normal 
in 24 hours, 
acidosis 
resolved at six 
days 
Case 2: mental 
status normal 
in 24 hours, 
acidosis 
resolved in 7 
days.  
Traub 
(11)  
2003 1 Unknown Agitation, 
Arching back 
movements, 
"can't feel 
anything" 
pH not reported, 
HCO3 20 mEq/L.  
Observation Full recovery 
in 24 hours. 
Langman 
(17) 
2003 1 Unknown Found dead in 
bed 
No data Not 
applicable 
Died 
Chung (8) 2004 1 800 mg Incoherence, 
Confusion, 
Disorientation, 
Echolalia 
pH 7.38, HCO3 
18 mEq/L 
Supportive Full recovery 
in 24 hours 
Ozer (13) 2004 1 25-50 mg 
daily for 7 
days 
Asymptomatic  pH 7.29, HCO3 
20 mEq/L 
Bicarbonate Acidosis 
resolved after 
bicarbonate. 
Burmeiste
r (14) 
2005 1 100 mg/day 
for 3 
months 
Asymptomatic pH 7.31, HCO3 
8.9 mEq/L 
Discontinued 
topiramate 
Lab 
abnormalities 
normalized at 
30 days.  
Lofton (3) 2005 567 12-2200 
mg 
Asymptomatic 
(62.1%), 
drowsiness/let
hargy (15.5%), 
dizziness/verti
go(4.9%), 
agitation(4.9%
), confusion 
(3.9%), 
nausea(2.6%), 
vomiting(2.5% 
Only one case 
with metabolic 
acidosis, no data 
on pH or 
bicarbonate 
Unspecified Unspecified 
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Lin (7) 2008 1 Unknown Confusion, 
visual 
hallucinations, 
slurred speech, 
ataxia. 
No data reported Observation Full recovery 
in 6 days.  
Mathews 
(19) 
2008 1 200-400 
mg/day 
Seizures HCO3 13 on day 
9 of hospital stay  
(nosocomial 
onset of acidosis 
following dose 
increase for 
seizures) 
Discontinued 
topiramate 
Full recovery 
in 10 days 
Wisniews
ki (2) 
2009 6 Range: 
750-12000 
mg 
Somnolence 
(66.7%); 
Vertigo, 
Agitation, & 
Mydriasis 
(33.4%), 
Seizure 
Mild to moderate 
metabolic 
acidosis in 4 of 7 
cases (pH range 
7.23 – 7.34, 
HCO3 range 
15.3-17.3 
mEq/L) 
Four received 
bicarbonate, 
two with 
supportive 
therapy 
Full recovery 
all patients 
Beyenbur
g(15) 
2009 1 150 mg/day Blurred Vision No data reported Discontinued 
topiramate 
Subjective 
improvement 
of vision after 
6 months 
Shiber 
(10) 
2010 1 No data Dyspnea, 
Tachycardia, 
Confusion, 
Respiratory 
Failure 
pH 7.14, HCO3 
11 mEq/L 
Mechanical 
ventilation 
for 
respiratory 
fatigue, 
Intravenous 
fluids and 
bicarbonate 
Full recovery 
in 72 hours 
Pierson 
(9) 
2010 1 400 mg Flushing, 
Anxiety, 
Tachycardia, 
Hypertension, 
Confusion 
pH 7.34, HCO3 
13 mEq/L  
Observation Full recovery 
in 24 hours 
Beer (24) 2010 1 Unknown Unresponsive 
in bed 
No data reported Resuscitation Died 
Lynch (6) 2010 1 Unknown 
overdose 
Coma, 
respiratory 
failure 
pH 7.26, HCO3 
16 mEq/L 
Intubated for 
airway 
protection, 
discontinued 
topiramate 
Full recovery 
in 72 hours 
Brandt 
(16) 
2010 1 ~20x200m
g tablets 
Non 
convulsive 
status 
epilepticus  
No data reported Discontinue 
topiramate, 
antiepileptics 
Full recovery 
in 10 days 
 
 
impaired ability to secrete acid in the 
collecting tubules, and type 2 or proximal 
RTA is characterized by a decreased 
reabsorption of filtered bicarbonate in the 
proximal tubule; both are mediated by a CA 
type II (major type in kidneys), which is 
inhibited by topiramate causing a mixed 
RTA [2, 21-24].  
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 Our patient probably ingested an 
unknown number of topiramate 100 mg 
immediate release tablets. One report 
described altered mental status in an adult 
following a single-dose of 400 mg of 
topiramate prescribed for migraine; a blood 
topiramate level drawn 15 hours after 
ingestion returned at 8.4 µg/mL, and 
symptoms resolved 24 hours after admission 
[11]. A 17 year old lady with suicidal intake 
of 800 mg of topiramate developed 
incoherence, confusion, disorientation, and 
speech impairments, but eventually had full 
resolution of symptoms within ~24 hours 
[10]. Most patients with topiramate toxicity 
recover relatively quickly with just 
supportive treatment [4, 5, 10, 11, 13]. In 
our literature search we found only two 
cases of fatal topiramate toxicity. The first 
case was a 41-year-old lady found 
unresponsive with bottles of topiramate, 
citalopram, and flunitrazepam at the scene. 
Autopsy and toxicology results reported a 
topiramate level of 49 µg/mL and 
citalopram level of 0.85 µg/mL, and the 
cause of death was stated to be topiramate 
intoxication in combination with citalopram. 
The other case was a 44-year-old lady found 
dead in bed, whose qualitative screening 
detected high concentrations of topiramate 
and the cause of death was attributed to it 
[19, 25].  
 Our patient’s serum topiramate level 
was 20.5 µg/mL. The reference range for 
serum topiramate is 2.0-8.0 µg/mL when 
used for psychiatric indications and 5.0-20.0 
µg/mL as an anticonvulsant. In studies 
conducted on topiramate for epilepsy, there 
were some patients who tolerated levels 
higher than this range and a few others who 
exhibited toxicity even within this 
therapeutic range [26]. Sampling for drug 
level monitoring is usually done prior to the 
next daily dose (trough), but definite toxic 
levels have not been well defined [26]. 
Based on the information from the family, 
we guessed that the last dose of topiramate 
was consumed 13 hours prior to drawing a 
sample for topiramate level. Topiramate 
exhibits linear pharmacokinetics (PK) over a 
dose range of 100 mg to 1200 mg immediate 
release tablets [1, 26, 27]. It is rapidly 
absorbed and almost completely achieves 
peak or maximal concentrations (Cmax) ~ 2 
hour post ingestion (range 1-4 hours) which 
is unaffected by food. It is poorly bound to 
plasma proteins, has a volume of 
distribution of 0.6 to 0.8 L/kg, and 75-80% 
of unchanged drug undergoes renal 
elimination resulting in a half-life between 
20-30 hours [1, 28]. The Cmax varies 
between 1.73 µg/mL to 28.7 µg/mL for the 
dose range of 100 mg to 1200 mg 
respectively. Based on these PK data, the 
reported level of 20.5 µg/mL at 13 hours 
post ingestion projects into an ingestion of at 
least 800 mg or higher dose of topiramate. 
Our patient’s clinical course is reminiscent 
of prior reports which stated that within a 
relatively short period of time and with only 
supportive treatment to correct acidosis the 
patient’s symptoms resolved. In summary, 
without a clear history, severe NAGMA was 
the key to the diagnosis of topiramate 
toxicity. Our case highlights the fact that 
topiramate must be suspected as a cause of 
severe NAGMA in those taking it when 
other causes are not apparent. 
 
CONCLUSION: 
 
Topiramate can cause severe symptomatic 
NAGMA and our review of literature 
suggests that this occurs even at therapeutic 
doses. Drug level testing is not widely 
available, but fortunately most cases recover 
with symptomatic treatment. It is important 
for physicians to be aware of such serious 
toxicity, because early diagnosis by high 
index of suspicion can improve outcomes.  
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